Aclaris TherapeuticsACRS +4.32%38 PS Ratio is 82.99 as of Jul. 02, 2026, which is 221% above its 10-year median of 25.82. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 933 Biotechnology companies, Aclaris Therapeutics ranks worse than 83.28% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aclaris Therapeutics's share price is $5.56.
Aclaris Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.07. Hence, Aclaris Therapeutics's PS Ratio for today is 82.99.
Warning Sign:
Aclaris Therapeutics Inc stock PS Ratio (=79.55) is close to 3-year high of 79.55.
The historical rank and industry rank for Aclaris Therapeutics's PS Ratio or its related term are showing as below:
ACRS'
s PS Ratio Range Over the Past 10 Years
Min: 2.09 Med: 25.82 Max: 1150.42
Current: 82.99
During the past 13 years, Aclaris Therapeutics's highest PS Ratio was 1150.42. The lowest was 2.09. And the median was 25.82.
ACRS's PS Ratio is ranked worse than 83.28% of 933
companies
in the Biotechnology industry
Industry Median: 9.46
vs ACRS: 82.99
Aclaris Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Aclaris Therapeutics was -67.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -48.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -6.10% per year.
During the past 13 years, Aclaris Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 64.70% per year. The lowest was -48.00% per year. And the median was 31.50% per year.
Back to Basics: PS Ratio
Aclaris Therapeutics (NAS:ACRS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Aclaris Therapeutics PS Ratio Related Terms
Aclaris Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Aclaris Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aclaris Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclaris Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Aclaris Therapeutics's Share Price of today is $5.56. Aclaris Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Aclaris Therapeutics (ACRS) has a PS Ratio of 82.99 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aclaris Therapeutics and its competitors. This is 221% above median its historical median of 25.82. Over the past decade, Aclaris Therapeutics' PS Ratio has ranged from 2.09 to 1,150.42. According to the industry distribution chart, Aclaris Therapeutics ranks #777 out of 933 companies in the Biotechnology industry, placing it in the top 83.3%.
Is Aclaris Therapeutics' PS Ratio too high?
Aclaris Therapeutics' current PS Ratio of 82.99 is 221% above median its 10-year median of 25.82. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 1,150.42. The Biotechnology industry median PS Ratio is 9.46. Aclaris Therapeutics' value of 82.99 is 777.3% above this industry median. Based on the distribution chart, Aclaris Therapeutics ranks #777 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' PS Ratio compare to RLMD and GYRE?
According to the Biotechnology industry distribution chart, Aclaris Therapeutics ranks #777 out of 933 companies for PS Ratio. This places Aclaris Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.46. Aclaris Therapeutics' value of 82.99 is 777.3% above this benchmark. Historically, Aclaris Therapeutics' own PS Ratio has ranged from 2.09 to 1,150.42 over the past decade. While the company's 10-year median is 25.82 vs. the industry median of 9.46, Aclaris Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.46, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aclaris Therapeutics's current PS Ratio of 82.99 is 777.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aclaris Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclaris Therapeutics's current PS Ratio is 82.99, which is 221% above median its own 10-year median of 25.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $5.56 — trading 1135.6% above its estimated fair value. The current PS Ratio is 82.99, which is 221% above median its 10-year median of 25.82 and 777.3% above the Biotechnology industry median of 9.46. Aclaris Therapeutics' overall GF Score™ is 38/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current PS Ratio is 82.99 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aclaris Therapeutics (ACRS) Overvalued in 2026?
Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued.
The current stock price of $5.56 is trading 1135.6% above its estimated GF Value™ of $0.45.
GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.
Key valuation signals for ACRS:
PS Ratio: 82.99 (221% above median its 10-year median of 25.82)
GF Value™: $0.45 vs. price of $5.56 (1135.6% above fair value)
Industry Position: 777.3% above the Biotechnology median (#777 of 933)
No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score
Get the complete analysis for ACRS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRS has been successfully added to your 
